IL327470A - מווסת מוליכות טרנסממברנלית של סיסטיק פיברוזיס - Google Patents
מווסת מוליכות טרנסממברנלית של סיסטיק פיברוזיסInfo
- Publication number
- IL327470A IL327470A IL327470A IL32747026A IL327470A IL 327470 A IL327470 A IL 327470A IL 327470 A IL327470 A IL 327470A IL 32747026 A IL32747026 A IL 32747026A IL 327470 A IL327470 A IL 327470A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- compounds
- substituted
- pharmaceutically acceptable
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363587955P | 2023-10-04 | 2023-10-04 | |
| PCT/US2024/049813 WO2025076235A1 (en) | 2023-10-04 | 2024-10-03 | Modulators of cystic fibrosis transmembrane conductance regulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327470A true IL327470A (he) | 2026-05-01 |
Family
ID=93257762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327470A IL327470A (he) | 2023-10-04 | 2024-10-03 | מווסת מוליכות טרנסממברנלית של סיסטיק פיברוזיס |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4788429A1 (he) |
| KR (1) | KR20260111143A (he) |
| CN (1) | CN122374316A (he) |
| AR (1) | AR134047A1 (he) |
| AU (1) | AU2024355979A1 (he) |
| CO (1) | CO2026005992A2 (he) |
| DO (1) | DOP2026000095A (he) |
| IL (1) | IL327470A (he) |
| TW (1) | TW202517241A (he) |
| UY (1) | UY40920A (he) |
| WO (1) | WO2025076235A1 (he) |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2881078C (en) | 2004-06-24 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| PT2404919E (pt) | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| ATE534383T1 (de) | 2006-05-12 | 2011-12-15 | Vertex Pharma | Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid |
| CA2989620C (en) | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| RS56894B1 (sr) | 2008-08-13 | 2018-04-30 | Vertex Pharma | Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje |
| WO2010037066A2 (en) | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| KR20160013251A (ko) | 2008-11-06 | 2016-02-03 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ-결합 카세트 수송자의 조절자 |
| SI3330255T1 (sl) | 2009-03-20 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi |
| EP2563778B1 (en) | 2010-03-25 | 2016-08-24 | Vertex Pharmaceuticals Incorporated | Crystalline form of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide |
| CN102811938B (zh) | 2010-04-09 | 2016-10-12 | 艾克索仿生技术公司 | 外骨骼负载处理系统及其使用方法 |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| NZ603042A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| CA2809263A1 (en) | 2010-08-27 | 2012-03-01 | Eleni Dokou | Pharmaceutical composition and administrations thereof |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| ME03652B (me) | 2011-05-18 | 2020-07-20 | Vertex Pharmaceuticals Europe Ltd | Deuterisani derivati ivakaftora |
| EP2819670B1 (en) | 2012-02-27 | 2026-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical Composition and Their Administration |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| KR102396897B1 (ko) | 2012-11-02 | 2022-05-13 | 버텍스 파마슈티칼스 인코포레이티드 | Ｃｆｔｒ 매개된 질환의 치료를 위한 약제학적 조성물 |
| WO2014078842A1 (en) | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
| PL3925607T5 (pl) | 2014-04-15 | 2026-06-01 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| HK1258472A1 (zh) | 2015-09-21 | 2019-11-15 | Vertex Pharmaceuticals (Europe) Limited | 氘代cftr增效剂的施用 |
| AU2017352206B2 (en) | 2016-10-27 | 2022-03-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated CFTR potentiators |
| CA3158057A1 (en) | 2019-11-12 | 2021-05-20 | Genzyme Corporation | 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity |
| MX2022005810A (es) | 2019-11-12 | 2022-06-08 | Genzyme Corp | Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente. |
| WO2021113809A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
| WO2021113808A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Cftr-modulating arylamides |
| WO2021113806A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| BR112023006470A2 (pt) * | 2020-10-07 | 2023-09-26 | Vertex Pharma | Moduladores de regulador de condutância transmembrana de fibrose cística |
| PE20231380A1 (es) | 2020-11-18 | 2023-09-07 | Vertex Pharma | Macrociclicos que contienen una anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quistica |
| WO2023012230A2 (en) | 2021-08-06 | 2023-02-09 | Telefonaktiebolaget Lm Ericsson (Publ) | Generative adversarial-based attack in federated learning |
| IL311038A (he) | 2021-09-03 | 2024-04-01 | Genzyme Corp | תרכובות אינדול ושיטות שימוש |
| WO2023034946A1 (en) | 2021-09-03 | 2023-03-09 | Genzyme Corporation | Indole compounds and uses thereof in the treatement of cystic fibrosis |
| US20250320226A1 (en) | 2022-02-03 | 2025-10-16 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
| AU2023273614A1 (en) | 2022-05-16 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20250340568A1 (en) | 2022-05-16 | 2025-11-06 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
-
2024
- 2024-10-03 CN CN202480076195.XA patent/CN122374316A/zh active Pending
- 2024-10-03 AU AU2024355979A patent/AU2024355979A1/en active Pending
- 2024-10-03 KR KR1020267013797A patent/KR20260111143A/ko active Pending
- 2024-10-03 IL IL327470A patent/IL327470A/he unknown
- 2024-10-03 EP EP24794995.1A patent/EP4788429A1/en active Pending
- 2024-10-03 WO PCT/US2024/049813 patent/WO2025076235A1/en not_active Ceased
- 2024-10-04 AR ARP240102707A patent/AR134047A1/es unknown
- 2024-10-04 TW TW113137925A patent/TW202517241A/zh unknown
- 2024-10-04 UY UY0001040920A patent/UY40920A/es unknown
-
2026
- 2026-04-01 DO DO2026000095A patent/DOP2026000095A/es unknown
- 2026-05-04 CO CONC2026/0005992A patent/CO2026005992A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024355979A1 (en) | 2026-05-21 |
| EP4788429A1 (en) | 2026-08-12 |
| KR20260111143A (ko) | 2026-07-14 |
| UY40920A (es) | 2025-04-30 |
| AR134047A1 (es) | 2025-11-26 |
| WO2025076235A1 (en) | 2025-04-10 |
| TW202517241A (zh) | 2025-05-01 |
| DOP2026000095A (es) | 2026-06-15 |
| CO2026005992A2 (es) | 2026-05-19 |
| CN122374316A (zh) | 2026-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL300224B1 (he) | מודולטורים של מוליך הרגולטור של סיסטיק פיברוזיס טרנסממברנה | |
| IL290408A (he) | מאפננים של מווסת מוליכות טרנס-ממברנלי של סיסטיק פיברוזיס | |
| IL315715A (he) | מודולטורים של סיסטיק פיברוזיס טרנס-ממברנה ויסות מוליכות | |
| IL286768A (he) | סוכני איפנון להולכת רגולטור לטרנסממברנה של סיסטיק פיברוזיס | |
| IL275049A (he) | תהליכים להכנת מודולטורים לווסת הולכה טרנסממברנלית של ציסטיק פיברוזיס | |
| IL274763B1 (he) | שיטות להכנת מאפננים של מווסת מוליכות טרנסממברנלי של סיסטיק פיברוזיס | |
| MX2023004072A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. | |
| PL3436446T3 (pl) | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa | |
| IL273163A (he) | מאפננים של חלבון מבקר הולכה טרנסממבראנלית של ציסטיק פיברוזיס ושיטות לשימוש | |
| IL212431A0 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| ZA200802172B (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| UY39459A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
| IL327468A (he) | צורות מוצקות של מווסת מוליכות טרנסממברנלית של סיסטיק פיברוזיס | |
| HK40122889A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HK40119219A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HK40098229A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HK40098238A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HK40098702A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HK40075439A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HK40075046A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| AU2024265267A1 (en) | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | |
| CA3291124A1 (en) | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | |
| HK40037541A (en) | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | |
| HK1159491A (en) | Modulators of cystic fibrosis transmembrane conductance regulator |